Every 10-Q that X4 Pharmaceuticals, Inc. (XFOR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals, a biopharma focused on rare hematology diseases, reported Q2 2026 revenue of $8.8 million, up from $2.0 million a year earlier, driven by license and other revenue from its Norgine partnership and higher net product sales of XOLREMDI, which reached $2.4 million. Net loss narrowed to $16.2 million from $25.7 million as research and development and general and administrative expenses declined following 2025 restructuring actions.
As of June 30, 2026, cash, cash equivalents and short‑term marketable securities totaled $208.0 million, with $40.4 million used in operating activities in the first half of 2026. Long‑term financing is anchored by the Hercules Loan Agreement, with $75.0 million of principal outstanding and total principal plus end‑of‑term payments of $77.0 million due July 1, 2027. Management expects current liquidity to fund operations and debt obligations for at least the next 12 months, while continuing to anticipate operating losses and the need to raise additional capital over time.
XOLREMDI has accelerated approval in the United States for WHIM syndrome and obtained European Commission marketing authorization in April 2026, with commercialization in Europe out‑licensed to Norgine and the approved MAA transferred in July 2026. The pivotal 4WARD Phase 3 trial in chronic neutropenia is ongoing under a new CRO, with an FDA meeting planned to revisit sample size and an enrollment update targeted by the end of the third quarter.
X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, reversing a small profit a year earlier as prior-year one-time license revenue from Norgine did not repeat. Total revenue was $2.7 million, including $2.5 million of U.S. XOLREMDI product sales and $0.2 million from its Norgine license.
Research and development expenses were $15.5 million and general and administrative expenses were $6.9 million, both down sharply following 2025 restructuring. X4 ended March 31, 2026 with $233.7 million in cash, cash equivalents and short-term marketable securities and $75.0 million of Hercules term debt.
During the quarter, X4 continued enrolling its global Phase 3 4WARD trial of mavorixafor in chronic neutropenia. On April 29, 2026, after quarter-end, the European Commission granted marketing authorization for XOLREMDI capsules to treat patients with WHIM syndrome in the European Union.
X4 Pharmaceuticals (XFOR) filed its Q3 2025 10‑Q, highlighting early commercial traction, a major partnership, and cost actions. Total revenue was $1.8 million for the quarter, driven by $1.6 million in U.S. product sales of XOLREMDI and $0.2 million of license and other revenue. For the nine months, revenue reached $32.5 million, primarily from $28.3 million recognized under the Norgine license and supply agreement.
The company reported a Q3 net loss of $29.8 million and a nine‑month net loss of $55.3 million. Cash, cash equivalents and short‑term marketable securities were $122.2 million as of September 30, 2025. Long‑term debt stood at $76.1 million. A 1‑for‑30 reverse stock split was effected on April 28, 2025.
X4 executed significant financings: approximately $81.0 million in net proceeds from an August private placement and approximately $145.6 million in net proceeds from an October underwritten offering. The company undertook two restructurings in 2025, including an additional ~50% workforce reduction announced in September, recording about $4.9 million of related Q3 charges and ending Q3 with $3.7 million of accrued severance. As of October 31, 2025, shares outstanding were 87,436,688.
X4 Pharmaceuticals reported modest product sales and a significant upfront license payment but remains under material financial strain. Total revenue was $1.97 million for the quarter (product revenue $1.74 million) and $30.78 million for the six months driven by a €28.5 million upfront and €0.5 million regulatory milestone from the Norgine license, of which $27.6 million was recognized as license revenue. The company recorded a net loss of $25.7 million for the quarter and $25.5 million year-to-date. Cash, cash equivalents and short-term marketable securities totaled about $63.0 million and total assets were $105.2 million.
Management completed a 1-for-30 reverse stock split and executed a purchase agreement with Lincoln Park for up to $40.0 million (240,000 shares sold for $0.5 million through June 30, 2025). Long-term debt outstanding was $75.0 million with $76.4 million of principal and end-of-term payments due July 1, 2027. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern due to expected covenant breaches under the Hercules loan agreement and the need to raise additional capital.